(Reuters) -Roivant and partner Priovant Therapeutics said on Wednesday that their experimental drug for a rare disease affecting both skin and muscle health has shown promising results in a late-stage clinical trial.

Shares of Roivant were up about 12% in premarket trading.

The drug, brepocitinib, was being tested for dermatomyositis, a condition that causes painful skin rashes and progressive muscle weakness, making everyday tasks difficult. If left untreated, the disease can severely impact a patient’s quality of life.

The companies said the drug showed improvement in both skin and muscle symptoms, reducing or stopping the need for steroids, which are commonly used to manage the disease but can cause long-term side effects.

In the trial, patients receiving a daily 30 mg oral dose of

See Full Page